Cardiac Failure, Critical Illness
Conditions
Keywords
ECMO, V-A ECMO, Oxidative stress, Oxygen, Hyperoxia
Brief summary
To compare the impact of liberal vs conservative oxygen doses on markers of oxidative stress in patients enrolled in the BLENDER trial.
Detailed description
Extracorporeal membrane oxygen (ECMO) is a heart lung support device used for patients with severe and cardiac and respiratory failure and carries an increased risk of exposure to very high oxygen tensions. Hyperoxia (arterial oxygen \>100mmHg) can lead to the production of reactive oxygen species (ROS). Excess production of ROS and depletion of antioxidant compounds is referred to as oxidative stress and results in inflammation, tissue injury and cell death. The inter-relationship between the production of ROS and end organ dysfunction is complicated and remain unclear. A more detailed assessment of the timing of changes in markers of oxidative stress, inflammatory mediators and tissue injury is warranted to understand the processes and potentially identify therapeutic targets. The BLENDER Trial is a multicentre trial in ECMO patients to determine whether a conservative oxygen strategy during ECMO reduces ICU length of stay and improves patient outcomes compared to a liberal oxygen strategy. Currently there have been no studies that look at the underlying pathophysiological changes that occur in patients on ECMO when subjected to different oxygen concentrations. As such The BLENDER study represents a unique opportunity to understand the mechanisms by which hyperoxia may cause tissue injury in patients receiving ECMO. This nested study seeks to elucidate whether exposure to hyperoxia during ECMO results in increased oxidative stress and whether this is correlated with increased risk of tissue injury and organ dysfunction. A better understanding of the mechanism of hyperoxia induced tissue injury may allow treatment to be optimised for patients exposed to hyperoxia as part of their treatment.
Interventions
None listed
Sponsors
Australian and New Zealand Intensive Care Research Centre
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Patients receiving venoarterial (VA) ECMO * Enrolled in the BLENDER trial
Exclusion criteria
* Not enrolled in the BLENDER trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Super oxide dismutase levels U/ml | Within 24 hours of ECMO commencement | Plasma levels of superoxide dismutase in patients exposed to either a liberal or conservative oxygen strategy during VA-ECMO |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Superoxide dismutase levels | On Day 7 following ECMO commencement | Plasma levels of superoxide dismutase in patients exposed to either a liberal or conservative oxygen strategy during VA-ECMO |
| Markers of Kidney Injury | Day 3 of ECMO | Creatinine (micromol/L) |
| Marker of Cardiac Injury | Day 3 of ECMO | Troponin ng/ml This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO |
| Markers of Liver Injury | Day 3 of ECMO | ALT and AST (IU/L) This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO |
| Coagulation Parameters | Day 3 of ECMO | APTT This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO |
| Immune Markers | Day 3 of ECMO | IL-6, TNFa, IL-10, IL-1B (pg/ml) |
| Other Markers of Oxidative Stress | Day 3 of ECMO | Malondialdehyde, Vitamin C |
| Superoxide dismutase levels U/ml | On Day 3 following ECMO commencement | Plasma levels of superoxide dismutase in patients exposed to either a liberal or conservative oxygen strategy during VA-ECMO |
| Marker of Neurological Injury | Day 3 of ECMO | Neuron Specific Enolase (microg/L) This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO |
Other
| Measure | Time frame | Description |
|---|---|---|
| Marker of Fibrinolysis | Day 3 of ECMO | Fibrinogen, Plasmin anti-plasmin complex, D-Dimer This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO |
Countries
Australia
Outcome results
None listed